Cintia Piccina

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Oxfordshire, United Kingdom
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Cintia Piccina
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Cintia Piccina

Form 4 holding Chief Commercial Officer

Allovir, Inc.

Security class
Common Stock
Shares / value
147,000
Estimated value
$98,608
Report date
03 Jul 2023
Price
$0.6708
Ownership
Direct
Form 4 holding Chief Commercial Officer

Adaptimmune Therapeutics PLC

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
18,421
Estimated value
$10,588
Report date
15 Jan 2025
Price
$0.5748
Ownership
Direct
Form 4 holding Chief Commercial Officer

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
1,074,696
Estimated value
Report date
20 Feb 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Commercial Officer

Allovir, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
273,000
Estimated value
Report date
03 Jul 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Cintia Piccina

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .